Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Chemotherapeutic agents subvert tumor immunity by generating agonists of platelet-activating factor.

Sahu RP, Ocana JA, Harrison KA, Ferracini M, Touloukian CE, Al-Hassani M, Sun L, Loesch M, Murphy RC, Althouse SK, Perkins SM, Speicher PJ, Tyler DS, Konger RL, Travers JB.

Cancer Res. 2014 Dec 1;74(23):7069-78. doi: 10.1158/0008-5472.CAN-14-2043. Epub 2014 Oct 10.

2.

Impaired PIASy-Tip60 signaling weakens activation of p53 in melanoma.

Lakhter AJ, Kanginakudru S, Warren S, Touloukian CE, Boissy RE, Naidu SR.

Melanoma Res. 2013 Jun;23(3):213-7. doi: 10.1097/CMR.0b013e328361056d.

PMID:
23624367
3.

The environmental stressor ultraviolet B radiation inhibits murine antitumor immunity through its ability to generate platelet-activating factor agonists.

Sahu RP, Turner MJ, DaSilva SC, Rashid BM, Ocana JA, Perkins SM, Konger RL, Touloukian CE, Kaplan MH, Travers JB.

Carcinogenesis. 2012 Jul;33(7):1360-7. doi: 10.1093/carcin/bgs152. Epub 2012 Apr 27.

4.

Transplantation of mouse HSCs genetically modified to express a CD4-restricted TCR results in long-term immunity that destroys tumors and initiates spontaneous autoimmunity.

Ha SP, Klemen ND, Kinnebrew GH, Brandmaier AG, Marsh J, Hangoc G, Palmer DC, Restifo NP, Cornetta K, Broxmeyer HE, Touloukian CE.

J Clin Invest. 2010 Dec;120(12):4273-88. doi: 10.1172/JCI43274. Epub 2010 Nov 15.

5.

High-avidity autoreactive CD4+ T cells induce host CTL, overcome T(regs) and mediate tumor destruction.

Brandmaier AG, Leitner WW, Ha SP, Sidney J, Restifo NP, Touloukian CE.

J Immunother. 2009 Sep;32(7):677-88. doi: 10.1097/CJI.0b013e3181ab1824.

6.

Tumor-specific Th17-polarized cells eradicate large established melanoma.

Muranski P, Boni A, Antony PA, Cassard L, Irvine KR, Kaiser A, Paulos CM, Palmer DC, Touloukian CE, Ptak K, Gattinoni L, Wrzesinski C, Hinrichs CS, Kerstann KW, Feigenbaum L, Chan CC, Restifo NP.

Blood. 2008 Jul 15;112(2):362-73. doi: 10.1182/blood-2007-11-120998. Epub 2008 Mar 19.

7.

Poor immunogenicity of a self/tumor antigen derives from peptide-MHC-I instability and is independent of tolerance.

Yu Z, Theoret MR, Touloukian CE, Surman DR, Garman SC, Feigenbaum L, Baxter TK, Baker BM, Restifo NP.

J Clin Invest. 2004 Aug;114(4):551-9.

8.

Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens.

Phan GQ, Touloukian CE, Yang JC, Restifo NP, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, White DE, Rosenberg SA.

J Immunother. 2003 Jul-Aug;26(4):349-56.

9.

Normal tissue depresses while tumor tissue enhances human T cell responses in vivo to a novel self/tumor melanoma antigen, OA1.

Touloukian CE, Leitner WW, Schnur RE, Robbins PF, Li Y, Southwood S, Sette A, Rosenberg SA, Restifo NP.

J Immunol. 2003 Feb 1;170(3):1579-85.

10.

MHC class I and class II presentation of tumor antigen in retrovirally and adenovirally transduced dendritic cells.

Sloan JM, Kershaw MH, Touloukian CE, Lapointe R, Robbins PF, Restifo NP, Hwu P.

Cancer Gene Ther. 2002 Nov;9(11):946-50.

11.

Expression of a "self-"antigen by human tumor cells enhances tumor antigen-specific CD4(+) T-cell function.

Touloukian CE, Leitner WW, Robbins PF, Li YF, Kang X, Lapointe R, Hwu P, Rosenberg SA, Restifo NP.

Cancer Res. 2002 Sep 15;62(18):5144-7.

12.

Assumptions of the tumor 'escape' hypothesis.

Restifo NP, Antony PA, Finkelstein SE, Leitner WW, Surman DP, Theoret MR, Touloukian CE.

Semin Cancer Biol. 2002 Feb;12(1):81-6. Review.

13.

Mining the melanosome for tumor vaccine targets: P.polypeptide is a novel tumor-associated antigen.

Touloukian CE, Leitner WW, Robbins PF, Rosenberg SA, Restifo NP.

Cancer Res. 2001 Nov 15;61(22):8100-4.

14.

Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules.

Zeng G, Touloukian CE, Wang X, Restifo NP, Rosenberg SA, Wang RF.

J Immunol. 2000 Jul 15;165(2):1153-9.

15.

Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice.

Touloukian CE, Leitner WW, Topalian SL, Li YF, Robbins PF, Rosenberg SA, Restifo NP.

J Immunol. 2000 Apr 1;164(7):3535-42.

16.
17.

Recombinant virus vaccination against "self" antigens using anchor-fixed immunogens.

Irvine KR, Parkhurst MR, Shulman EP, Tupesis JP, Custer M, Touloukian CE, Robbins PF, Yafal AG, Greenhalgh P, Sutmuller RP, Offringa R, Rosenberg SA, Restifo NP.

Cancer Res. 1999 Jun 1;59(11):2536-40.

18.

Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes.

Overwijk WW, Lee DS, Surman DR, Irvine KR, Touloukian CE, Chan CC, Carroll MW, Moss B, Rosenberg SA, Restifo NP.

Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):2982-7.

19.

Lotus lectin labels subpopulation of olfactory receptor cells.

Stewart WB, Touloukian CE.

Chem Senses. 1996 Feb;21(1):13-8.

PMID:
8646487

Supplemental Content

Loading ...
Support Center